↓ Skip to main content

Obinutuzumab vs rituximab for advanced DLBCL: a PET-guided and randomized phase 3 study by LYSA

Overview of attention for article published in Blood, April 2021

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (89th percentile)
  • High Attention Score compared to outputs of the same age and source (87th percentile)

Mentioned by

twitter
14 X users
guideline
3 clinical guideline sources

Readers on

mendeley
50 Mendeley